Contents
The goal of medical studies is simple: provide state-of-the-art and comprehensive care. Clinical research in Idaho offers the perfect opportunity for leading medical technology and pharmaceutical companies to revamp currently available treatments, drugs, and therapies.
Health volunteers are the backbone of medical discoveries. It is with your help that we make this possible.
Clinical Trials For Disease Areas in Idaho
Clinical research trials in Idaho are versatile. They target many diseases to find innovative solutions. Such as heart disease, neurological complications, bone and joint-related ailments, retinal conditions, and more.
The state of Idaho is also famous for its cancer research. Back in 2019, The Idaho State University Accelerator Center reported they could make a very pure type of medical isotope copper-67. This could be used in clinical trials to see how well it fights cancer.
Ready to make a difference? Browse our list below to find clinical trials you can apply for.
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: Saint Luke's Mountain States Tumor Institute, Boise, Idaho
Saint Luke's Mountain States Tumor Institute, Boise, Idaho
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Read Less
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: Saint Luke's Mountain States Tumor Institute, Boise, Idaho
Saint Luke's Mountain States Tumor Institute, Boise, Idaho
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Patient Retrospective Outcomes (PRO)
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Pain and Spine Specialists of Idaho, Idaho Falls, Idaho +1 locations
Pain and Spine Specialists of Idaho, Idaho Falls, Idaho
North Idaho Day Surgery, Post Falls, Idaho
Conditions: Chronic Pain
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Recruiting
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, wor... Read More
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho
Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho
Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: St. Luke Regional Medical Center, Boise, Idaho
St. Luke Regional Medical Center, Boise, Idaho
Conditions: Parkinson's Disease
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +12 locations
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Saint Luke's Cancer Institute - Boise, Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho
Walter Knox Memorial Hospital, Emmett, Idaho
Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho
Idaho Urologic Institute-Meridian, Meridian, Idaho
Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Saint Alphonsus Medical Center-Nampa, Nampa, Idaho
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Kootenai Cancer Clinic, Sandpoint, Idaho
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +7 locations
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho
Walter Knox Memorial Hospital, Emmett, Idaho
Idaho Urologic Institute-Meridian, Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Project: Every Child for Younger Patients With Cancer
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. Read Less
Gender:
ALL
Ages:
25 years and below
Trial Updated:
08/08/2025
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm, Adrenal Gland Pheochromocytoma, Malignant Neoplasm, Neoplasm of Uncertain Malignant Potential, Childhood Kidney Neoplasm
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +12 locations
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Saint Luke's Cancer Institute - Boise, Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho
Walter Knox Memorial Hospital, Emmett, Idaho
Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho
Idaho Urologic Institute-Meridian, Meridian, Idaho
Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Recruiting
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE).
The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will... Read More
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE).
The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will assess the effect of amlitelimab when compared to placebo on gluten induced changes in the intestinal mucosa as measured by the villous height to crypt depth (Vh:Cd) ratio. The effect of amlitelimab on participant-reported celiac signs and symptoms along with the safety, tolerability, and pharmacokinetics of amlitelimab will also be studied.
Study details include:
The study duration will be up to 48 weeks (including a 16-week safety follow-up period) with 10 visits for participants who opt not to enter the optional long-term extension.
The study duration will be up to 172 weeks (including an 8-week safety follow-up period) with 22 visits for participants who enter the optional long-term extension.
The double-blind placebo-controlled treatment duration will be up to 28 weeks. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Centre Hospitalier Universitaire de Bordeaux - Hopital Pellegrin Tripode- Site Number : 8400006, Bordeaux, Idaho
Centre Hospitalier Universitaire de Bordeaux - Hopital Pellegrin Tripode- Site Number : 8400006, Bordeaux, Idaho
Conditions: Coeliac Disease, Celiac Disease
Paid Clinical Trials in Idaho
Paid clinical trials open new doors for both researchers and health volunteers. By participating, you can get compensated for your work. This makes ID paid clinical trials a go-to choice for those looking to earn some cash or mitigate their medical expenses.
Phase 1 trials offer the biggest payment. They come with more risks (i.e. testing new medicine, unpredictable side effects, etc.), restrictions (i.e. don’t drink, follow a specific diet, don’t smoke, etc.), and are time-consuming. Phase 4 trials pay the least. Check the trial benefits before you apply.
Clinical Trials For Health Volunteers in Idaho
Your contribution not only advances cutting-edge treatments but also offers hope and a chance at a better future. Research teams in Idaho need health volunteers to propel their studies forward and make meaningful contributions to healthcare.
Find your path to medical discovery. Apply for trials today. Browse our list of clinical trials and be a part of the next breakthrough in medicine.
No trials could be found at this time
Medical Discoveries and Innovation in Idaho
Idaho research trials have left a mark on the field of healthcare. Here are some of the most impactful medical achievements that changed the lives of many patients.
- Telehealth Technology: Out of 44 Idaho counties, 35 are rural. Their access to healthcare is limited. So, the state made it a top priority to adopt telehealth technologies and revolutionize healthcare delivery. ID is now a leader in telemedicine.
- Environmental Factors Research: Experts from Idaho have collected substantial data that showcase the impact of climate change. The state’s changing climate conditions can help better understand how the summer and winter temperatures can affect agriculture, diseases, wildlife, and air quality.
- Studies of Infectious Diseases: Idaho’s Society of Epidemiologic Research is the oldest and biggest epidemiology society in North America. Experts from the community are actively involved in studying infectious diseases and treatments.
Why Idaho Is A Great Place For Clinical Research
Idaho clinical research can’t advance without the help of its people. Data shows that 81.1% of its residents are White, 13.3% are Hispanic, 2.2% are Multiracial, 1.5% are Asian, 1.1% are American Indian, 0.8% are Black.